Articles tagged with Prostate Tumors
A large population study found that smoking increases the risk of dying from prostate cancer, regardless of tumor stage, and is associated with a poorer prognosis. Smokers have a lower risk of developing prostate cancer but are more likely to be diagnosed at an advanced stage.
A new study by Weill Cornell Medicine investigators found that T cells' genetic program and developmental path affect their response to immunotherapy. The results suggest that infiltrating T cells don't all meet the same fate in every tumor, with long-lived memory programs correlating strongly with overall survival
A novel nuclear medicine combination therapy combining <sup> 177 </sup> Lu-PSMA-617 with idronoxil (NOX66) has been shown to be safe and effective in reducing PSA levels by over 50% in men with metastatic prostate cancer. The median overall survival was 19.7 months, suggesting potential for improved patient outcomes.
Levi A. Garraway is being honored for his groundbreaking contributions to cancer research, including the identification of melanoma genes and development of precision oncology approaches. He has also championed parallel sequencing as a definitive approach to tumor genomic profiling, revolutionizing cancer treatment strategies.
Researchers at Massachusetts General Hospital have found that cancer cells expressing certain kinases are more responsive to targeted therapies. These findings may help tailor treatments to individual patients based on the specific types and levels of protein expression in their tumors.
Scientists at University College London have developed a novel cancer therapy using magnetic seeds guided by an MRI scanner to heat and destroy tumours. The therapy, called MINIMA, has the potential to precisely treat hard-to-reach cancers with minimal side effects.
A meta-analysis published in The Lancet Oncology reveals that men with intermediate- and high-risk prostate cancer experience improved overall survival with the addition of hormone therapy to radiotherapy. The study found prolonged adjuvant hormone therapy benefits men, while neoadjuvant hormone therapy did not.
Researchers have identified NDUFS1 and ATP5O as novel markers of aggressive prostate cancer, associated with poorer survival rates. The study's findings provide new insights into the disease's molecular mechanisms and potential targets for therapy.
Surgeons at Henry Ford Health performed the world's first precision prostatectomy through the bladder using a single port robotic surgical system. The procedure preserves a portion of the prostate capsule, improving functional outcomes such as erectile function and urinary control.
Researchers have developed a prostate cancer organoid that can mimic the patient-specific microenvironment, opening up new avenues for targeted treatments. The study reveals that extracellular matrix regulates EZH2 activity and efficacy of inhibitors, as well as identifies potential new therapeutic targets like DRD2.
Researchers have developed a new approach to studying prostate cancer, allowing them to track the behavior of individual cancer cells from birth to organ spread. The technique uses whole-organ imaging and artificial intelligence to create a 3D reconstruction of the organ at single-cell resolution.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
A new pilot study reveals a prostate cancer urine test can identify men with intermediate-risk disease, allowing them to opt for active surveillance instead of immediate treatment. The test assesses the amount of aggressive cancer in the prostate without needing a biopsy.
A study analyzing 6,775 patients with low-risk prostate cancer found that cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment. The study also found that higher Gleason grade, PSA level, tumor stage, and number of positive biopsy cores are related to shorter conversion times.
A novel blood test, Stockholm3, can reduce the number of MRIs performed by a third while preventing the detection of minor, low-risk tumours. The addition of this test to MRI reduces overdiagnosis by as much as 69% and halves the number of biopsies.
Researchers have found a way to harness the power of immunotherapy for advanced prostate cancer by targeting a protein called PIKfyve. Blocking PIKfyve with the inhibitor ESK981 has been shown to increase tumor death and recruit immune T cells, offering new hope for patients with this challenging form of cancer.
Researchers identified a subset of localized prostate cancers that exhibit characteristics typical of 'hot' tumors, which may respond to immunotherapies. The study found that about a quarter of high-risk prostate cancers have these immunologic traits, suggesting a substantial number of patients may benefit from immunotherapy.
Researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer. Inhibiting the protein H6PD leads to significantly reduced tumor sizes and improved survival among mouse models with drug-resistant prostate cancer.
A new approach uses T cell engineering to deliver the gene coding for IL-24, which targets cancer cells regardless of their expression of target molecules. This method blocks tumor growth, starves tumors of nutrients, and generates memory T cells that can theoretically kill tumors if they recur.
Tumor gene profiling decreases patient acceptance of active surveillance among men with clinically similar prostate cancers and low health literacy, a new study found. The study suggests that education on prostate cancer treatment options is needed for this population.
A new study found that a high rate of genetic mutations within a tumor (high tumor mutation burden) can predict clinical responses to immune checkpoint inhibitors in certain cancer types, such as melanoma, lung and bladder cancer. However, this was not the case for other cancers, including breast, prostate and brain cancers.
Researchers at the University of Bern developed a new strategy to assess therapy response in prostate cancer patients. They created patient-derived organoids that retain relevant characteristics of the original tumors, allowing for targeted drug testing and potential treatment repurposing.
A study by researchers at UCLA Jonsson Comprehensive Cancer Center found that MRI frequently underestimates the size of prostate tumors, which can lead to undertreatment. The accuracy of treatment depends on precise measurements of both tumor size and PI-RADS score.
A clinical trial combining microbubbles with radiation therapy has shown promising results in treating liver cancer. The treatment increased tumor response rates by 93% compared to standard radiation alone, and improved patient outcomes, including longer overall survival and reduced need for retreatments.
Researchers at Memorial Sloan Kettering Cancer Center found that tumors with high mutation burden, particularly those with BRCA2 mutations, respond better to immunotherapy. This discovery may lead to more precise treatments for patients with BRCA2 mutations.
Research reveals that African American men's prostate cancer tumors have higher frequencies of certain genetic alterations compared to white men. These alterations may contribute to more aggressive disease and higher mortality rates among Black men.
Researchers at UT Southwestern Medical Center have discovered two experimental drugs that can suppress the growth and spread of non-small cell lung cancer (NSCLC) by affecting its blood vessels, oxygen levels, and other environmental factors. The findings highlight the potential of these drugs for NSCLC treatment.
Researchers developed a simplified process to estimate radiation dose using a single post-treatment SPECT/CT scan, potentially improving therapeutic outcomes by tailoring treatments to individual patients' physiology. The method was applied to 177Lu-PSMA-617 therapy for metastatic prostate cancer.
Researchers found the AZIN1 gene associated with metastatic prostate cancer, with reduced expression leading to fewer metastases. Further investigation is needed to confirm findings in all prostate cancers.
Targeted radionuclide therapy has been shown to improve the effectiveness of immunotherapies in treating prostate cancer by modifying the tumor microenvironment. The treatment can achieve immunomodulation at relatively low radiation doses without affecting the normal immune system.
Researchers identified four subtypes of prostate cancer with distinct characteristics, affecting treatment strategies and potentially improving patient outcomes. The study's findings suggest that one subtype requires intensified treatments while another is less aggressive, paving the way for more targeted therapies.
A new mathematical model predicts prostate cancer tumor growth and invasiveness based on stromal ecology, revealing that highly reactive stroma drives aggressive tumors. The model was validated in animal models and patients, suggesting improved prognosis with ecological metrics.
A clinical trial has identified a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment. The study found that these tumors had lower androgen receptor activity and higher stemness, making them more adaptable and resistant to treatment.
Researchers have developed a unique immunotherapy delivery system that can turn cold tumors into 'hot' tumors, making it effective in cancers such as breast and melanoma. The system uses a protein called interleukin 12 to inflame the tumor and activate the immune system.
The iPS87 cell line is characterized as a cancer-inducing, stem cell-like cell line that can be used to develop novel treatments for prostate cancer. After 8 transfers, the cultured cells lost their tumor-inducing capability and stem cell marker expression.
The study found that SRK-181 inhibits latent TGFβ1 activation with high selectivity and overcomes primary resistance to checkpoint blockade therapy by altering the tumor immune landscape. Preclinical results demonstrated improved preclinical safety profiles compared to conventional inhibitors of TGFβ signaling.
Researchers in Brazil identified a gene expression profile associated with cachexia, a potentially fatal syndrome characterized by severe weight loss and muscle wasting. The study found that pancreatic, esophageal, colorectal, stomach, and head-and-neck cancers are most frequently linked to cachexia.
Researchers identified novel PMEPA1-e isoform and characterized its biological functions in prostate cancer. The study found that the methylation of PMEPA1 gene promoter accounts for silencing of PMEPA1 in prostate cancer cells.
Researchers found that blocking androgen receptors can increase the density of prostate-specific membrane antigen (PSMA) sites on tumor surfaces, allowing for more targeted radiation therapy. This breakthrough could lead to more efficient treatment of advanced prostate cancer.
Researchers discovered that reactivating the PPP2R2A gene can slow or stop prostate cancer progression. The study found that patients with only one functional copy of the gene have shorter survival rates, and that reconstituting PP2A protein ultimately kills prostate cancer cells.
A study by researchers at the University of Texas M.D. Anderson Cancer Center identified a subset of immune macrophages that resist treatment with anti-PD-1 checkpoint blockade in glioblastoma patients. The team found that these CD73-expressing macrophages were associated with decreased survival, and that targeting them with combinatio...
A phase II clinical trial found that a small proportion of men with end-stage prostate cancer responded to pembrolizumab, an immunotherapy treatment, and lived for two years or more. The study identified a group of patients with DNA repair gene mutations who responded particularly well to the treatment.
A new radiation therapy regimen combining lutetium-177 and actinium-225 has been shown to stabilize tumour growth and improve survival rates for patients with late-stage prostate cancer. The study demonstrated significant reductions in side effects, including dry mouth, compared to previous radionuclide therapies.
Researchers discovered a new way to optimize PSMA-targeted prostate cancer treatment by adjusting peptide concentrations, reducing tumor uptake and salivary gland damage. The study suggests that setting an optimal molar activity level can minimize adverse effects while maintaining therapeutic efficacy.
A biomedical engineer at Worcester Polytechnic Institute is creating a new medical robot that uses photoacoustic imaging to detect and analyze three different indicators of prostate cancer. The system aims to be more accurate than current tests like ultrasounds and biopsies, while eliminating the need for radioactive contrast dye.
A clinical trial demonstrates the safety and feasibility of gold-silica nanoshells for treating localized prostate cancer, showing no serious side effects during treatment. The vast majority of treated lesions showed no evidence of tumor after 12 months.
A new treatment uses cellular soldiers created from the body's own defenses to track down and kill escaping cancer cells during surgeries, preventing metastasis. The innovative method has shown promise in clinical trials with triple negative breast cancer patients, increasing five-year survival rates.
Scientists at IDIBELL-ICO describe a novel mechanism of resistance to therapies that prevent blood vessel formation, which involves immune cells acting as tumor malignant elements. The study highlights the importance of targeting Sema4D and its secretion by macrophages to inhibit this mechanism.
Researchers have identified a signaling pathway regulating macropinocytosis in pancreatic tumors, which could lead to personalized treatments. The study reveals that tumors can dynamically adjust their nutrient uptake, with some 'dialing up' or 'dialing down' macropinocytosis based on glutamine availability.
Researchers at Oregon State University have developed an improved technique for using magnetic nanoclusters to kill hard-to-reach tumors. The nanoclusters, which can reach temperatures in excess of 100 degrees Fahrenheit, were found to be effective in treating ovarian cancer and other types of cancer.
Researchers have developed a genetically modified virus that kills cancer cells and makes them sensitive to chemotherapy drugs, halting tumor progression in mice. The combination of p53 gene therapy and cabazitaxel resulted in full control of tumor growth, with an additive or synergistic effect.
Researchers discovered that low levels of syntaphilin at the central core of prostate tumors correlate with increased risk of metastasis. The biomarker may identify patients who require more aggressive management and treatment.
A new method for predicting proton range has been introduced into clinical routine, reducing irradiated healthy tissue by 35-40%. This innovation improves treatment planning, making proton therapy more accurate and safer.
Researchers identified a phenomenon where cancer cells export PD-L1 in exosomes, remotely disarming immune cells and preventing them from attacking tumors. This discovery may help explain immunotherapy resistance and hints at new strategies to unleash the immune system against disease.
Scientists from Sanford Burnham Prebys Medical Discovery Institute identified how prostate cancer becomes treatment-resistant NEPC following targeted treatment. They found that an FDA-approved drug holds potential as a NEPC treatment and uncovered new therapeutic avenues to prevent transformation.
A new study suggests that enlarged prostates could impede tumor growth in prostate cancer patients. Computer simulations found that the mechanical stresses from an enlarging prostate keep tumors small. The findings challenge traditional treatments that involve downsizing the prostate.
A recent study analyzed over 8,000 human tumors and discovered common molecular hallmarks of low oxygen levels, which can predict cancer aggressiveness and inform treatment decisions. The findings provide new insights into the complex relationship between hypoxia, genetic changes, and tumor evolution.
A Columbia professor has developed a predictive computer platform that analyzes all tumor types and predicts effective treatment options. The platform, OncoTreat, is based on advanced data science techniques, including information theory and ray-tracing.
Researchers developed a computer model predicting prostate cancer progression using tumor genomes from nearly 300 patients. This enables clinicians to develop tailor-made treatments, potentially improving patient outcomes.
Researchers have identified NSD2 as a new vulnerability in aggressive, metastatic prostate cancers that have become resistant to hormonal therapies. The study suggests a combined therapeutic approach using an NSD2 inhibitor drug with conventional antiandrogenic drugs to re-sensitize resistant tumors.